ProQR Announces the Grant of two Key Patents, protecting QR-010 for Cystic Fibrosis in the US and EU Press release Key Updates April 03, 2017
ProQR Presents in vivo Proof of Concept Data for the Axiomer® RNA Editing Platform Technology Press release Key updates September 21, 2017
ProQR Announces Clinical Data Presentations and Investor & Analyst Event at NACFC Press release LEIDEN, the Netherlands, Sept. 27, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. September 27, 2016
ProQR Receives Fast Track Designation from FDA for QR-010 for Cystic Fibrosis Press release LEIDEN, the Netherlands, July 19, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. July 19, 2016
ProQR Appoints David M. Rodman, MD as Chief Development Strategy Officer Press release LEIDEN, the Netherlands, March 27, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) today announced that it appointed David M. Rodman, MD as Chief Development Strategy Officer. Dr. March 27, 2017
ProQR Completes Dosing of Cystic Fibrosis Patients in QR-010 Phase 1b Trial Press release Key Updates August 29, 2017
ProQR to present QR-010 data at the European Cystic Fibrosis Society Conference and provides an update on the ongoing Phase 1b trial Press release Key Updates June 08, 2017
ProQR to Release Topline Data from Proof of Concept Study of QR-010 in Cystic Fibrosis Patients at NACFC Press release LEIDEN, the Netherlands, June 21, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. June 21, 2016
ProQR Announces Axiomer® RNA Editing Licensing and Research Collaboration with Lilly Press release Companies will collaborate to develop editing oligonucleotides directed to up to five targets using ProQR’s proprietary Axiomer® RNA edit September 08, 2021